Novartis Pharmaceuticals VP of Business Development Salaries in Boston
The average Novartis Pharmaceuticals VP of Business Development in Boston earns $365,000 annually, which includes a base salary of $280,000 with a $85,000 bonus. This total compensation is $153,899 more than the US average for a VP of Business Development.
In Boston, The Business Development Department at Novartis Pharmaceuticals earns $2,371 more on average than the Sales Department. Comparably data has a total of 1 salary record from Novartis Pharmaceuticals VPs of Business Development.
Last updated 2 years ago.
- $280,000
- avg. base
- $85,000
- avg. bonus
VP of Business Development Salaries at Novartis Pharmaceuticals
In Boston, VPs of Business Development earn $185,000 more than Directors of Business Development.
Compensation at Novartis Pharmaceuticals by Department
In Boston, The Business Development Department averages $2,371 more than the Sales Department, and $1,172 less than the HR Department
Recent VP of Business Development Salaries at Novartis Pharmaceuticals
VP of Business Development Compensation by Gender (All Companies)
The average female VP of Business Development at companies similar size to Novartis Pharmaceuticals reported making $315,250, while the average male VP of Business Development at similar sized companies reported making $283,234.
VP of Business Development Compensation by Ethnicity (All Companies)
The average Caucasian VP of Business Development at companies similar size to Novartis Pharmaceuticals reported making $304,764, while the average African American/Black VP of Business Development at similar sized companies reported making $140,000.
How VPs of Business Development at Novartis Pharmaceuticals Rate Their Compensation
The majority of VPs of Business Development at Novartis Pharmaceuticals believe they're compensated fairly. 100% of VPs of Business Development at Novartis Pharmaceuticals say they receive annual bonuses, and the vast majority (79%) are satisfied with their benefits. See more compensation ratings at Novartis Pharmaceuticals
